Galantamine, a cholinesterase inhibitor, is being evaluated for its efficacy and safety in treating Alzheimer's disease. The market for Alzheimer's therapeutics is substantial, with increasing prevalence due to aging populations. The competitive landscape includes other cholinesterase inhibitors and novel mechanisms targeting amyloid and tau pathology. Successful outcomes could position Janssen favorably in a market with significant unmet needs, particularly for patients with moderate Alzheimer's disease. Diligence should focus on the drug's safety profile, potential market access hurdles, and existing competitive products.